leadf
logo-loader
viewRedx Pharma PLC

Redx Pharma to welcome new chief medical officer in March 2021

The current CMO, Dr Andrew Saunders, is moving on to pursue other opportunities but Redx has secured the services of Dr Jane Robertson, a vastly experienced haemato-oncologist, to replace him

Redx Pharma PLC -

Redx Pharma PLC (LON:REDX), the drug discovery and development company focused on cancer and fibrosis has appointed Dr Jane Robertson as its chief medical officer.

She is a well respected UK haemato-oncologist with more than 17 years' experience of clinical development in oncology (cancer treatment) and has a breadth of experience investigating multiple tumours and agents.

Dr Robertson is currently the chief medical officer at Achilles Therapeutics, a biotech company focused on the creation of a personalised T cell therapy directed against clonal tumour neoantigens. She will commence her role at Redx at the beginning of March next year.

She has previously held a number of senior research & development leadership roles at AstraZeneca Oncology, notably leading the development of the first in class PARP inhibitor, olaparib.

She will take over from Dr Andrew Saunders following a handover period. Dr Saunders is quitting Redx to pursue other opportunities.

“As our chief medical officer, her extensive and varied experience in big pharma, biotech and clinical practice will be invaluable as we further progress our pipeline into clinical development,” said Lisa Anson, the chief executive officer of Redx in a statement.

"On behalf of all of Redx and the board, I would like to thank Andrew for his great work in overseeing the transition of RXC004 into phase 1 and his strategic guidance in our planned future development plans for RXC004," Anson added.

Quick facts: Redx Pharma PLC

Price: 57.5 GBX

AIM:REDX
Market: AIM
Market Cap: £112.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

RedX Pharma presents at the Proactive One2One Virtual Conference

Redx Pharma's (LON:REDX) Lisa Anson pitches to investors at the One2One Proactive virtual forum. The company is focused on the development of novel targeted medicines to validated anti-cancer and fibrosis targets in areas of unmet need. Redx Pharma uses its proven drug discovery expertise...

4 weeks, 1 day ago

2 min read